Cardiometabolic Therapy and Mortality in Very Old Patients With Diabetes Hospitalized due to COVID-19
Author(s) -
Juan Carlos Ramos Ramos,
Luis M. PérezBelmonte,
Francisco Javier Carrasco-Sánchez,
Sergio JansenChaparro,
Mercedes de-Sousa-Baena,
José Bueno-Fonseca,
Maria Pérez-Aguilar,
Coral Arévalo-Cañas,
Marta Bacete Cebrián,
Manuel MéndezBailón,
Isabel Fiteni Mera,
Andrés González García,
Francisco Navarro Romero,
Carlota Tuñón de Almeida,
Gemma Muñiz Nicolás,
Amara González Noya,
Almudena Hernández Milian,
Gema María García García,
José Nicolás Alcalá Pedrajas,
Virginia Herrero García,
Luis CorralGudino,
Pere Comas Casanova,
Héctor Meijide Míguez,
José Manuel Casas Rojo,
Ricardo GómezHuelgas
Publication year - 2021
Publication title -
the journals of gerontology series a
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.134
H-Index - 189
eISSN - 1758-535X
pISSN - 1079-5006
DOI - 10.1093/gerona/glab124
Subject(s) - medicine , odds ratio , diabetes mellitus , confidence interval , observational study , dipeptidyl peptidase 4 , type 2 diabetes , type 2 diabetes mellitus , logistic regression , angiotensin converting enzyme , blood pressure , endocrinology
Background The effects of cardiometabolic drugs on the prognosis of diabetic patients with COVID-19, especially very old patients, are not well known. This work was aimed to analyze the association between preadmission cardiometabolic therapy (antidiabetic, antiaggregant, antihypertensive, and lipid-lowering drugs) and in-hospital mortality among patients ≥80 years with type 2 diabetes mellitus (T2DM) hospitalized for COVID-19. Method We conducted a nationwide, multicenter, observational study in patients ≥80 years with T2DM hospitalized for COVID-19 between March 1 and May 29, 2020. The primary outcome measure was in-hospital mortality. A multivariate logistic regression analysis was performed to assess the association between preadmission cardiometabolic therapy and in-hospital mortality. Results Of the 2 763 patients ≥80 years old hospitalized due to COVID-19, 790 (28.6%) had T2DM. Of these patients, 385 (48.7%) died during admission. On the multivariate analysis, the use of dipeptidyl peptidase-4 inhibitors (adjusted odds ratio [AOR] 0.502, 95% confidence interval [CI]: 0.309–0.815, p = .005) and angiotensin receptor blockers (AOR 0.454, 95% CI: 0.274–0.759, p = .003) were independent protectors against in-hospital mortality, whereas the use of acetylsalicylic acid was associated with higher in-hospital mortality (AOR 1.761, 95% CI: 1.092–2.842, p = .020). Other antidiabetic drugs, angiotensin-converting enzyme inhibitors, and statins showed neutral association with in-hospital mortality. Conclusions We found important differences between cardiometabolic drugs and in-hospital mortality in older patients with T2DM hospitalized for COVID-19. Preadmission treatment with dipeptidyl peptidase-4 inhibitors and angiotensin receptor blockers could reduce in-hospital mortality; other antidiabetic drugs, angiotensin-converting enzyme inhibitors, and statins seem to have a neutral effect; and acetylsalicylic acid could be associated with excess mortality.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom